Sponsors

Lead Sponsor

Nova Scotia Health Authority

Participants will be recruited from the weight loss surgery waitlist and randomly assigned to a brief (5 sessions) ACT intervention or to waitlist control group. A mobile app will be used to encourage daily ACT skill practice and track health behaviours over time. The primary objective of the proposed project is to test whether a brief ACT intervention can result in sustained weight management (at 6 months and 1 year) compared to a waitlist control group. If this brief format of ACT intervention for obesity proves to be effective in encouraging health behaviours and weight loss, it may provide a low cost, sustainable option to enhance much needed obesity management services in Nova Scotia.

Related studies

RECRUITING

Five PLus Year EffIcacy of Endoscopic Sleeve Gastroplasty (ESG) for Sustained WeigHT Loss

NCT06894498 · Obesity and Obesity-related Medical Conditions, Weight Loss

RECRUITINGNA

Intensive Glycemic Targets in Overweight and Obese Women With Gestational Diabetes

NCT05124808 · Gestational Diabetes, Pregnancy, High Risk, and more

RECRUITINGPhase 3

Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

NCT06937086 · Ulcerative Colitis, Obesity or Overweight

RECRUITINGPhase 3

A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity

NCT07595549 · Obesity, Overweight and/or Obesity, and more

RECRUITINGPhase 3

Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes

NCT07284875 · Obesity, Overweight

View all related studies →

The Role of Values, Acceptance, and Mindfulness Strategies in Long Term Weight Management

What this study is about

Save this trial guide to your notes

Sponsors

Related studies

Five PLus Year EffIcacy of Endoscopic Sleeve Gastroplasty (ESG) for Sustained WeigHT Loss

Intensive Glycemic Targets in Overweight and Obese Women With Gestational Diabetes

Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity

Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes

Trial snapshot

Condition

Locations shown

For caregivers